Online inquiry

IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10834MR)

This product GTTS-WQ10834MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets PD-L1; TGFBR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2; NM_001024847.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126; 7048
UniProt ID Q9NZQ7; P37173
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10834MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3055MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ13911MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ10998MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ1686MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ10938MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ4557MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ15603MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ5124MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW